IP Library › Granted Patent US 12,576,048
Granted Patent B2
US 12,576,048 · App. 17/311,101 · Granted Mar 17, 2026

Anti-cancer activity of adamantane derivatives

Inventor: Andrew Sharabi (San Diego, CA)
Assignee: The Regents of the University of California
A61K31/13A61K31/16A61K45/06A61P35/00A61K47/60
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,576,048
App. No.
17/311,101
Granted
Mar 17, 2026
Kind
B2
Abstract

Provided herein are methods for treating cancer comprising administering to a subject in need thereof an adamantane derivative, or a pharmaceutically acceptable salt thereof, such as rimantadine or amantadine. In some embodiments, the adamantane derivative is PEGylated.

Claims (19)

1 . A method of treating a head and neck squamous cell carcinoma in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of rimantadine, or a pharmaceutically acceptable salt thereof.

2 . The method of claim 1 , wherein the subject is administered a pharmaceutically acceptable salt of rimantadine.

3 . The method of claim 2 , wherein the pharmaceutically acceptable salt of rimantadine is a hydrochloride salt.

4 . The method of claim 1 , wherein cells of the head and neck squamous cell carcinoma express a human papilloma virus (HPV) protein.

5 . The method of claim 4 , wherein the HPV protein is one or more of an E5, E6, or E7 protein.

6 . The method of claim 5 , wherein the HPV E5, E6, or E7 protein is from one or more HPV subtypes selected from the group consisting of: HPV 6, HPV 11, HPV 16, HPV 18, HPV 31, HPV 33, HPV35, HPV 39, HPV 45, HPV51, HPV 52, HPV 56, HPV 48, HPV 66, and HPV 69.

7 . The method of claim 6 , wherein the HPV protein is HPV 16 E5.

8 . The method of claim 1 , wherein the head and neck squamous cell carcinoma is HPV-associated cancer.

9 . A method of treating a head and neck squamous cell carcinoma in a subject, the method comprising:

contacting a cell of said head and neck squamous cell carcinoma in the subject, said cell comprising an HPV E5 protein, with

a therapeutically effective amount of rimantadine, or a pharmaceutically acceptable salt thereof.

10 . The method of claim 1 , wherein the method further comprises administering at least one additional anti-cancer agent.

11 . The method of claim 10 , wherein the at least one additional anti-cancer agent is selected from the group consisting of: carboplatin, cisplatin, gemcitabine, methotrexate, paclitaxel, pemetrexed, lomustine, temozolomide, dacarbazine, and any combination thereof.

12 . The method of claim 10 , wherein the at least one additional anti-cancer agent is an immunotherapy agent.

13 . The method of claim 10 , wherein the at least one additional anti-cancer agent is an immune checkpoint inhibitor.

14 . The method of claim 13 , wherein the immune checkpoint inhibitor targets one or more of: CTLA-4, PD-1, PD-L1, BTLA, LAG-3, A2AR, TIM-3, B7-H3, VISTA, and IDO.

15 . The method of claim 13 , wherein the immune checkpoint inhibitor is selected from the group consisting of: ipilimumab, nivolumab, pembrolizumab, atezolizumab, avelumab, durvalumab, cemiplimab-rwlc, tremelimumab, cemiplimab, and any combination thereof.

16 . The method of claim 1 , wherein the method further comprises subjecting the subject to radiation therapy, surgery, or any combination thereof.

17 . The method of claim 1 , wherein the subject is a human.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 9, 2021
From: SHARABI, ANDREW
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 056479/0789 →
Continuity (2)
Provisional Application 62775731 · Dec 5, 2018
Related Publication 20210330605A1 · Oct 28, 2021
References Cited (35)
US 5061703A · Bormann et al. · 1991 [cited by applicant]
US 20110190291A1 · Renslo et al. · 2011 [cited by applicant]
US 20110218241A1 · Preston et al. · 2011 [cited by applicant]
US 20110293705A1 · Irvine et al. · 2011 [cited by applicant]
US 20130072553A1 · Xu · 2013 [cited by applicant]
US 20150290160A1 · Cheng et al. · 2015 [cited by applicant]
US 20180215699A1 · Humbert et al. · 2018 [cited by applicant]
US 20200399348A1 · Wieland et al. · 2020 [cited by applicant]
CN 102070463 · 2011 [cited by applicant]
WO WO2014075187 · 2014 [cited by applicant]
WO WO2019164970A1 · 2019 [cited by applicant]
Um, S. H. et al. Variable expression of the forgotten oncogene E5 in HPV-positive oropharyngeal cancer. J Clin Virol., 2014. vol. 61(1): 94-100. (Year: 2014). [cited by examiner]
Rzeski et al., “Glutamate antagonists limit tumor growth,” Proceedings of the National Academy of Sciences, May 22, 2001, 98(11):6372-6377. [cited by applicant]
Wetherill et al., “Alkyl-imino sugars inhibit the pro-oncogenic ion channel function of human papillomavirus (HPV) E5,” Antiviral Research, Oct. 1, 2018, 158:113-121. [cited by applicant]
Wetherill et al., “High-risk human papillomavirus E5 oncoprotein displays channel-forming activity sensitive to small-molecule inhibitors,” Journal of Virology, May 1, 2012, 86(9):5341-5351. [cited by applicant]
Cohen et al., “Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (Keynote-040): a randomised, open-label, phase 3 study,” Lancet, Jan. 2019, 393… [cited by applicant]
Conway et al., “Replication and Assembly of Human Papillomaviruses,” Journal of Dental Research, Apr. 2009, 88(4):307-317. [cited by applicant]
Extended European Search Report in European Appln No. 19892331.0, dated Jan. 20, 2022, 10 pages. [cited by applicant]
Ferris et al., “Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck,” The New England Journal of Medicine, Nov. 2016, 375(19):1856-1867. [cited by applicant]
Hoppe-Seyler et al., “The HPV E6/E7 Oncogenes: Key Factors for Viral Carcinogenesis and Therapeutic Targets,” Trends in Microbiology, Feb. 2018, 26(2):158-168. [cited by applicant]
International Preliminary Report on Patentability in International Appln. No. PCT/US2019/064760, dated Jun. 8, 2021, 7 pages. [cited by applicant]
International Search Report and Written Opinion in International Appln. No. PCT/US2019/064760, dated Apr. 23, 2020, 10 pages. [cited by applicant]
Kubler et al., “Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study,” Journal for Immuno Therapy of Cancer, Jun. 2015, 3:26, 14 pages. [cited by applicant]
Miyauchi et al., “HPV16 E5 Mediates Resistance to PD-L1 Blockade and can be Targeted with Rimantadine in Head and Neck Cancer,” Cancer Research, Dec. 2019, 80(4):732-746. [cited by applicant]
O'Brien et al., “Evasion of host immunity directed by papillomavirus-encoded proteins,” Virus Research, Sep. 2002, 88:103-117. [cited by applicant]
Pardi et al., “mRNA vaccines—a new era in vaccinology,” Nature Review—Drug Discovery, Apr. 2018, 17(4): 261-279. [cited by applicant]
Rausch et al., “mRNA vaccine CV9103 and CV9104 for the treatment of prostate cancer,” Human Vaccines & Immunotherapeutics, Nov. 2014, 10(11): 3146-3152. [cited by applicant]
Seiwert et al., “Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (Keynote-012): an open-label, multicentre, phase 1b trial,” Lancet Onc… [cited by applicant]
Senba et al., “Mechanisms of virus immune evasion lead to development from chronic inflammation to cancer formation associated with human papillomavirus infection,” Oncology Reviews, Oct. 2012, 6(2)(e17):135-144. [cited by applicant]
Venuti et al., “Papillomavirus E5: the smallest oncoprotein with many functions,” Molecular Cancer, Nov. 2011, 10:140, 18 pages. [cited by applicant]
Veronese et al., “PEGylation, successful approach to drug delivery,” Drug Discovery Today, Nov. 2005, 10(21):1451-1458. [cited by applicant]
Hier et al., “A Murine Model for the Immunotherapy of Head and Neck Squamous Cell Carcinoma,” The Laryngoscope, Oct. 1995, 105(10):1077-1080. [cited by applicant]
Office Action in European Appln. No. 19892331.0 mailed on Jan. 16, 2025, 6 pages. [cited by applicant]
Shindoh et al., “Detection of human papillomavirus DNA sequences in oral squamous cell carcinomas and their relation to p53 and proliferating cell nuclear antigen expression, ” Cancer, Nov. 1, 1995, 76(9):1513-1521. [cited by applicant]
Benevolo et al., “Immunohistochemical expression of p16(INK4a) is predictive of HR-HPV infection in cervical low-grade lesions, ” Modern Pathology, Jan. 1, 2006, 19(3):384-391. [cited by applicant]